← Back
$ELVN All transactions

Enliven Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$1.2M

Shares

45,000

Price

$26

Filed

Feb 19

Insider

Name

Collins Helen Louise

Title

CHIEF MEDICAL OFFICER

CIK

0001701247

Roles

Officer

Transaction Details

Transaction Date

2026-02-17

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

25,000

Footnotes

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. | This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. | All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Filing Info

Accession No.

0001701247-26-000002

Form Type

4

Issuer CIK

0001672619

Collins Helen Louise's History

Date Ticker Type Value
2026-04-17 ELVN M $12K
2026-04-17 ELVN $6K
2026-04-17 ELVN $115K
2026-04-17 ELVN $117K
2026-04-17 ELVN M $0
2026-03-25 ELVN M $99K
2026-03-25 ELVN $1.4M
2026-03-25 ELVN M $0
2026-02-17 ELVN M $112K
2026-02-17 ELVN $1.2M

Other Insiders at ELVN (90d)

Insider Bought Sold Last
Garland J. Scott 2026-02-12
Kunkel Lori Anne 2026-02-12
Gupta Rishi 2026-02-12
Heyman Richard A. $32K 2026-02-17
Bauer Jake 2026-02-12
Collins Helen Louise
CHIEF MEDICAL OFFICER
$1.6M 2026-04-17
Ballal Rahul D. 2026-02-12
Derynck Mika K 2026-02-12
Hohl Benjamin
CHIEF FINANCIAL OFFICER
2026-02-12
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
$145K 2026-02-12
Patel Anish
CHIEF OPERATING OFFICER
2026-02-12